"A Phase Ib, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Non-Muscle-Invasive Urothelial Carcinoma of the Bladder NCT02720367", ClinicalTrials.gov, 24 March 2016 (2016-03-24), XP055439485, Retrieved from the Internet: URL:https://clinicaltrials.gov/archive/NCT 02720367/2016_03_24 [retrieved on 2017-06-07] (B1)

Anonymous: "A Phase lb, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Muscle-Invasive Transitional Cell Carcinoma of the Bladder NCT02722538", ClinicalTrials.gov, 2 May 2016 (2016-05-02), XP055439481, Retrieved from the Internet: URL:https://clinicaltrials.gov/archive/NCT 02722538/2016_05_02 [retrieved on 2017-06-07] (B1)

Anonymous: "TARIS Biomedical Announces Positive Results from Ph1b Trial of TAR-200 (GemRISTM) in Patients with Muscle Invasive Bladder Cancer | Business Wire", , 6 January 2017 (2017-01-06), XP055639407, Retrieved from the Internet: URL:https://www.businesswire.com/news/home /20170106005117/en/TARIS-Biomedical -Announces-Positive-Results-Ph1b-Trial [retrieved on 2019-11-06] (B1)

BIDNUR, S. et al.: "Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer", Bladder Cancer, vol. 2, no. 1, 7 January 2016 (2016-01-07) , pages 15-25, XP055439493, (B1)

COCKERILL, P.A. et al.: "Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer", BJU Int., vol. 117, no. 3, 23 May 2015 (2015-05-23), pages 456-462, XP055439488, (B1)

US-A1- 2015 250 717 (B1)

OH K S ET AL: "Combined-Modality Therapy With Gemcitabine and Radiation Therapy as a Bladder Preservation Strategy: Long-Term Results of a Phase I Trial", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, USA, vol. 74, no. 2, 1 June 2009 (2009-06-01), pages 511-517, XP026094986, ISSN: 0360-3016, DOI: 10.1016/J.IJROBP.2008.08.021 [retrieved on 2008-10-30] (B1)

SHARIAT, S.F. et al.: "Update on intravesical agents for non-muscle-invasive bladder cancer", Immunotherapy, vol. 2, no. 3, May 2010 (2010-05), pages 381-392, XP9512850, (B1)

SKINNER, E.C. et al.: "SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer and Recurrence after 2 Prior Courses of Intravesical Bacillus Calmette-Guerin", The Journal of Urology, vol. 190, no. 4, 2013, pages 1200-1204, XP028712640, (B1)

STERNBERG ITAY A ET AL: "Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guérin Treatment Failure", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 190, no. 5, 7 May 2013 (2013-05-07), pages 1686-1691, XP028734145, ISSN: 0022-5347, DOI: 10.1016/J.JURO.2013.04.120 (B1)

US-A1- 2015 165 178 (B1)

LI, J. et al.: "Effect of internal iliac artery chemotherapy after transurethral resection of bladder tumor for muscle invasive bladder cancer", Chin J Cancer Res., vol. 26, no. 5, October 2014 (2014-10), pages 558-563, XP055439490, (B1)